Pure Global AI
NCT05750758Not yet recruiting

Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty

A Randomized Controlled Trial of Rivaroxaban Combined With Dual Antiplatelet Therapy Versus Dual Antiplatelet Therapy Alone 1 Month After Drug-coated Balloon Angioplasty in Patients With Acute Coronary Syndrome Without High Bleeding Risk
Henan Institute of Cardiovascular EpidemiologyClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Acute Coronary Syndrome
Drug/Device/Intervention
rivaroxaban
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Henan Institute of Cardiovascular Epidemiology
Timeline & enrollment
Phase
N/A
Start date
Feb 20, 2023
End date
Apr 01, 2024
Enrollment
120 participants
Primary outcome

Loss of lumen area of target vessel

Summary

The target population of this interventional study was ACS patients with drug-coated
 balloons. The main discussion : 1.1 months of rivaroxaban combined with dual antiplatelet
 therapy compared with dual antiplatelet therapy alone, late lumen loss at 6 months. 2. To
 determine the safety of the regimen with bleeding events as the end point. Subjects were
 randomly assigned to two groups, one receiving routine DAPT for six months and one receiving
 DAPT plus one month of rivaroxaban 2.5 mg bid

ICD-10 classifications
Acute myocardial infarctionAcute myocardial infarction, unspecifiedAcute subendocardial myocardial infarctionAcute ischaemic heart disease, unspecifiedOther acute ischaemic heart diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05750758
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05750758 through Pure Global AI's free database. This phase not specified trial is sponsored by Henan Institute of Cardiovascular Epidemiology and is currently Not yet recruiting. The study focuses on Acute Coronary Syndrome. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.